Filtered By:
Drug: Pradaxa
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 1455 results found since Jan 2013.
The association between direct oral anticoagulant concentration upon acute stroke and stroke outcome
CONCLUSION: Among DOAC users who developed IS, low drug concentrations at hospital presentation predicted poor outcomes.PMID:36990874 | DOI:10.1016/j.ejim.2023.03.023
Source: European Journal of Internal Medicine - March 29, 2023 Category: Internal Medicine Authors: Shin-Yi Lin Sung-Chun Tang Ching-Hua Kuo Chih-Hao Chen Yuan-Chang Chao Chih-Fen Huang Jiann-Shing Jeng Source Type: research
Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants
AbstractLarge-scaled post-marketing surveillance studies (PMSSs) of 4 direct oral anticoagulants (DOACs) for stroke prevention in non-valvular atrial fibrillation (AF) were conducted since 2011 in Japan, and the results of the last one have recently been published. Each reported a more than acceptable ischemic stroke prevention. The major bleeding rates were also acceptably low and comparable to each other in the PMSSs of dabigatran (J-dabigatran), rivaroxaban (XAPASS), and edoxaban (ETNA-AF-Japan). However, the incidence in PMSS of apixaban (STANDARD) was more than double the others. This finding appeared to contradict th...
Source: European Journal of Clinical Pharmacology - March 14, 2023 Category: Drugs & Pharmacology Source Type: research
Drug-drug interactions with direct oral anticoagulants for the prevention of ischemic stroke and embolism in atrial fibrillation: a narrative review of adverse events
Expert Rev Clin Pharmacol. 2023 Mar 2. doi: 10.1080/17512433.2023.2187376. Online ahead of print.ABSTRACTINTRODUCTION: In randomized trials, direct oral anticoagulants (DOAC) were non-inferior to the vitamin-K-antagonist (VKA) warfarin in preventing stroke/embolism in patients with atrial fibrillation (AF). DOAC are substrates for P-glycoprotein (P-gp), CYP3A4 and CYP2C9. The activity of these enzymes is modulated by several drugs which might induce pharmacokinetic drug-drug interactions (DDI). Drugs affecting platelet function have the potential for pharmacodynamic DDI of DOAC.AREAS COVERED: The literature was searched fo...
Source: Expert Review of Clinical Pharmacology - March 2, 2023 Category: Drugs & Pharmacology Authors: Claudia St öllberger Birke Schneider Josef Finsterer Source Type: research
Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review
AbstractOlder adults, the fastest growing population, represent almost 50% of all users of direct oral anticoagulants (DOACs). Unfortunately, we have very little relevant pharmacological and clinical data on DOACs, especially in older adults with geriatric profiles. This is highly relevant as pharmacokinetics and pharmacodynamics (PK/PD) often differ substantially in this population. Hence, we need to obtain a better understanding of the PK/PD of DOACs in older adults, to ensure appropriate treatment. This review summarises the current insights into PK/PD of DOACs in older adults. A search was undertaken up to October 2022...
Source: Clinical Pharmacokinetics - March 2, 2023 Category: Drugs & Pharmacology Source Type: research
Discovery and development of Factor Xa inhibitors (2015 –2022)
This article summarizes the small molecule Factor Xainhibitors developed from 2015 to 2022, classifies them according to their scaffolds, focuses on the analysis of their structure-activity relationships, and provides a brief assessment of them.
Source: Frontiers in Pharmacology - February 21, 2023 Category: Drugs & Pharmacology Source Type: research
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study
CONCLUSION: Among patients with AF and chronic liver disease, DOACs as a class were associated with lower risks of hospitalization for ischemic stroke/systemic embolism and major bleeding versus warfarin. However, the incidence of clinical outcomes among patients with AF and chronic liver disease varied between individual DOACs and warfarin, and in head-to-head DOAC comparisons.PMID:36762560 | DOI:10.1161/CIRCULATIONAHA.122.060687
Source: Circulation - February 10, 2023 Category: Cardiology Authors: Oluwadolapo D Lawal Herbert D Aronow Fisayomi Shobayo Anne L Hume Tracey H Taveira Kelly L Matson Yichi Zhang Xuerong Wen Source Type: research
